The impact of Spike mutations on SARS-CoV-2 neutralization
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Multiple SARS-CoV-2 vaccines have shown protective efficacy, which is most likely mediated by neutralizing antibodies recognizing the viral entry protein, Spike. Antibodies from SARS-CoV-2 infection neutralize the virus by focused targeting of Spike and there is limited serum cross-neutralization of the closely-related SARS-CoV. As new SARS-CoV-2 variants are rapidly emerging, exemplified by the B.1.1.7, 501Y.V2 and P.1 lineages, it is critical to understand if antibody responses induced by infection with the original SARS-CoV-2 virus or the current vaccines will remain effective against virus variants. In this study we evaluate neutralization of a series of mutated Spike pseudotypes including a B.1.1.7 Spike pseudotype. The analyses of a panel of Spike-specific monoclonal antibodies revealed that the neutralizing activity of some antibodies was dramatically reduced by Spike mutations. In contrast, polyclonal antibodies in the serum of patients infected in early 2020 remained active against most mutated Spike pseudotypes. The majority of serum samples were equally able to neutralize the B.1.1.7 Spike pseudotype, however potency was reduced in a small number of samples (3 of 36) by 5–10-fold. This work highlights that changes in the SARS-CoV-2 Spike can alter neutralization sensitivity and underlines the need for effective real-time monitoring of emerging mutations and their impact on vaccine efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Spike mutation D614G alters SARS-CoV-2 fitness
Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., Fontes-Garfias, C. R., et al. (2021) · Nature · doi:10.1038/s41586-020-2895-3 · Cited by 1,558
Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419
Self-citationGreaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178 · cited 5×
“Notably, binding analysis has suggested mutations in this loop can reduce RBD binding by Spike-specific sera (Greaney et al., 2021).”
BackgroundResultInfluentialGreaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
SARS-CoV-2 evolution during treatment of chronic infection
Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I. A. T. M., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C., Mlcochova, P., Lumb, I. U., et al. (2021) · Nature · doi:10.1038/s41586-021-03291-y · Cited by 1,097
Self-citationD614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Weissman, D., Alameh, M.-G., de Silva, T., Collini, P., Hornsby, H., Brown, R., LaBranche, C. C., Edwards, R. J., Sutherland, L., Santra, S., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2020.11.012 · Cited by 324
Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70
Kemp, S. A., Meng, B., Ferriera, I. A., Datir, R., Harvey, W. T., Papa, G., Lytras, S., Collier, D. A., Mohamed, A., Gallo, G., et al. (2020) · doi:10.1101/2020.12.14.422555 · Cited by 252
Self-citationKidd, M., Richter, A., Best, A., Cumley, N., Mirza, J., Percival, B., Mayhew, M., Megram, O., Ashford, F., White, T., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab082 · Cited by 237
Research works printed but not linked: 34
- Andreano, E. , Piccini, G. , Licastro, D. , Casalino, L. , Johnson, N. V. , Paciello, I. , … Rappuoli, R. (2020). SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. · DOI · Paper page
- 10.1126/science.abc5902 · DOI · Paper page
- 10.1126/science.1225416 · DOI · Paper page
- 10.1016/j.cell.2020.05.025 · DOI · Paper page
- CDC, 2003, Update: Outbreak of severe acute respiratory syndrome--worldwide, 2003, MMWR Morb Mortal Wkly Rep, 52, 241
- Cevik, M. , Kuppalli, K. , Kindrachuk, J. , & Peiris, M. (2020). Virology, transmission, and pathogenesis of SARS-CoV-2. BMJ, 371. · DOI · Paper page
- 10.3390/v12020135 · DOI · Paper page
- Kemp, S. A. , Collier, D. A. , Datir, R. , Ferreira, I. A. , Gayed, S. , Jahun, A. , … Gupta, R. K. (2020). Neutralising antibodies drive Spike mediated SARS-CoV-2 evasion. medRxiv. · DOI
- Kidd, M. , Richter, A. , Best, A. , Mirza, J. , Percival, B. , Mayhew, M. , … McNally, A. (2020). S-variant SARS-CoV-2 is associated with significantly higher viral loads in samples tested by ThermoFisher TaqPath RT-QPCR. medRxiv. · DOI
- 10.1016/j.cell.2020.06.043 · DOI · Paper page
- 10.1038/s41586-020-2180-5 · DOI · Paper page
- 10.1016/j.cell.2020.07.012 · DOI · Paper page
- 10.1038/nature02145 · DOI · Paper page
- 10.1126/science.1086616 · DOI · Paper page
- 10.1016/j.immuni.2020.10.023 · DOI · Paper page
- 10.1038/s41586-020-03041-6 · DOI · Paper page
- Mor, M. , Werbner, M. , Alter, J. , Safra, M. , Chomsky, E. , Hada-Neeman, S. , … Freund, N. T. (2020). Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors. bioRxiv. · DOI
- 10.1126/science.abe1107 · DOI · Paper page
- 10.1038/s41375-020-01103-2 · DOI
- 10.17179/excli2020-1167 · doi:10.17179/excli2020-1167 · Paper page
- Oude Munnink, B. B., Sikkema, R. S. , Nieuwenhuijse, D. F. , Molenaar, R. J. , Munger, E. , Molenkamp, R. , … Koopmans, M. P. G. (2020). Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science. · DOI · Paper page
- 10.1016/S1473-3099(20)30484-9 · DOI · Paper page
- 10.1086/589862 · DOI · Paper page
- 10.1038/s41586-020-2456-9 · DOI · Paper page
- 10.1086/651022 · DOI · Paper page
- Rosa, A. , Pye, V. E. , Graham, C. , Muir, L. , Seow, J. , Ng, K. W. , … Cherepanov, P. (2021). SARS-CoV-2 recruits a haem metabolite to evade antibody immunity. In preparation. · DOI
- 10.1016/j.cell.2020.08.012 · DOI · Paper page
- 10.7554/eLife.61312 · DOI · Paper page
- 10.1093/ve/veaa094 · DOI
- 10.1371/journal.ppat.1009089 · DOI
- Xie, X. , Zou, J. , Fontes-Garfias, C. R. , Xia, H. , Swanson, K. A. , Cutler, M. , … Shi, P.-Y. (2021). Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv. · DOI · Paper page
- Xu, C. , Wang, Y. , Liu, C. , Zhang, C. , Han, W. , Hong, X. , … Cong, Y. (2021). Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Science Advances, 7. · DOI · Paper page
- 10.1038/s41423-020-0458-z · DOI · Paper page
- 10.1093/infdis/jiy696 · DOI
Cited by
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Self-citationAntibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
Planas, D., Bruel, T., Grzelak, L., Guivel-Benhassine, F., Staropoli, I., Porrot, F., Planchais, C., Buchrieser, J., Rajah, M. M., Bishop, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01318-5 · Cited by 697
Metadata
- Authors
- Rees-Spear, C., Muir, L., Griffith, S., Heaney, J., Aldon, Y., Snitselaar, J., Thomas, P., Graham, C., Seow, J., Lee, N., Rosa, A., Roustan, C., Houlihan, C., Sanders, R., Gupta, R., Cherepanov, P., Stauss, H., Nastouli, E., Doores, K., van Gils, M., & McCoy, L.
- Venue
- bioRxiv (Cold Spring Harbor Laboratory)
- Publisher
- openRxiv
- Published
- 2021-01-19
- OpenAlex
- W3122275632
- Cited by
- 45
- References
- 11
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of Spike mutations on SARS-CoV-2 neutralization. https://app.cochat.ai/papers/10.1101/2021.01.15.426849
- The paper
- Rees-Spear, C., Muir, L., Griffith, S., Heaney, J., Aldon, Y., Snitselaar, J., Thomas, P., Graham, C., Seow, J., Lee, N., Rosa, A., Roustan, C., Houlihan, C., Sanders, R., Gupta, R., Cherepanov, P., Stauss, H., Nastouli, E., Doores, K., . . . McCoy, L. (2021). The impact of Spike mutations on SARS-CoV-2 neutralization. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2021.01.15.426849
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.